View the latest updates on One Nucleus careers conferece, Building Life Science Adventures 2023.
Join us for the annual Building Life Science Adventures (BLSA) careers conference on 28-29 March 2023. Creating careers, not just jobs, is a two-way process between those seeking to build their adventures in science and those seeking to build the best teams. This One Nucleus careers conference is free to attend and a chance to fill knowledge gaps, debate best practice and connect to enable success.
• New logo and website created to reflect Leaf’s progression
• Better user experience with in-depth information on services and R&D
Norwich, UK - 24 January 2023 Leaf Expression Systems (Leaf), a plant-based contract research and product development company working to serve the global life sciences (human and animal health), agribiotech, food and consumer care industries has launched a new logo and website, leafexpressionsystems.com.
The EU Commission launched the process regarding the adoption of an adequacy decision for EU-U.S. How the #adequacydecision for United States will improve #datatransfers between EU and U.S.?
Click here to view the January 2023 edition of The Meeting Place.
Monday 23rd January 2022: Creative Places is delighted to announce the appointment of Liam Nicholls to the position of CEO. Liam takes over from Jonathan Burroughs, who will remain fully involved in the business, focusing on client work. |
o2h discovery, a preclinical Contract Research Organization which has an integrated drug discovery platform, is pleased to announce the second edition of the o2h kickstarter competition exclusively aimed towards supporting Australian early stage biotech companies. After the overwhelming response to the first competition, we are back with another edition to specifically support early stage Aus Biotech in their drug discovery programmes.
Howard Group appoints Hilson Moran as Sustainability Consultant for its flagship development Unity Campus
|
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA
License milestone to develop and commercialise ready-to-use medicine achieved
Arecor regains rights to AT282 following portfolio review at Hikma